Catabasis Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Catabasis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Catabasis Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.
Catabasis Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertriglyceridemia, with 2 trials.
Top-decile sponsor footprint
Catabasis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects
NCT04543370
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT03917719
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT03703882
Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
NCT02439216
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
NCT02608697
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
NCT02374047
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
NCT01968720
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
NCT01912560
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
NCT01725594
A Study of CAT-1004 Biomarkers in Healthy Subjects
NCT01670773
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
NCT01511900
Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers
NCT01440166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 3 |
| Phase 3 | 2 |
How the Catabasis Pharmaceuticals early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).
Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Hypertriglyceridemia (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Catabasis Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Catabasis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Catabasis Pharmaceuticals page
12 registered trials is a research-attention snapshot, not an endorsement of Catabasis Pharmaceuticals or any single study.
- None of Catabasis Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertriglyceridemia is the condition Catabasis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertriglyceridemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Catabasis Pharmaceuticals pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.